
-
Novavax NASDAQ:NVAX Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
Location: 21 Firstfield Rd, Maryland, 20878-1757, US | Website: www.novavax.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
619.1M
Cash
923.1M
Avg Qtr Burn
-21.82M
Short % of Float
28.93%
Insider Ownership
8.80%
Institutional Own.
60.18%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Update | ||
Nuvaxovid (NVX-CoV2373) Details COVID-19 | Approved Update | |
Approved Update | ||
Nuvaxovid (NVX-CoV2705) Details COVID-19 | Approved Update | |
Phase 3 Update | ||
COVID-Influenza combination (CIC) vaccine Details Influenza, COVID-19 | Phase 3 Initiation | |
NanoFlu vaccine Details Influenza | Phase 2 Initiation | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued | |
RSV Vaccine Details Respiratory syncytial virus | Failed Discontinued |